ABBV logo AbbVie +
AbbVie
+

AbbVie (ABBV) Business News

Track AbbVie in real time with a live news feed covering AbbVie stock news, official press releases, company announcements, and an archive of historical AbbVie news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
3:26 PM | Friday | Aug 14, 2026 The Motley Fool

AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

News Thumbnail
2:30 PM | Friday | Aug 14, 2026 Zacks Investment Research

Can ABBV's Neuroscience Drugs Drive Growth in the Second Half of 2026?

News Thumbnail
7:15 AM | Friday | Aug 14, 2026 Fool - Investing News

Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?

News Thumbnail
7:15 AM | Friday | Aug 14, 2026 Fool - Investing News

Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?

News Thumbnail
7:53 AM | Thursday | Aug 13, 2026 247 Wallst

Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More

News Thumbnail
12:12 PM | Wednesday | Aug 12, 2026 24/7 Wall Street

The Energy and Pharma Giants Quietly Funding HDV's 3% Yield, and How Safe Each One Is

News Thumbnail
6:45 AM | Tuesday | Aug 11, 2026 The Motley Fool

AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?

News Thumbnail
4:02 AM | Tuesday | Aug 11, 2026 Defense World

AbbVie Inc. $ABBV Shares Sold by Contravisory Investment Management Inc.

News Thumbnail
9:45 AM | Monday | Aug 10, 2026 24/7 Wall Street

We Said These 4 Dividend Aristocrats Could Soar. Here's How They Did, Plus 3 New Picks.

News Thumbnail
9:44 AM | Monday | Aug 10, 2026 The Motley Fool

Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?

News Thumbnail
8:00 AM | Monday | Aug 10, 2026 24/7 Wall Street

3 Beaten-Down Healthcare Stocks to Buy in August

News Thumbnail
4:24 PM | Friday | Aug 7, 2026 The Motley Fool

AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026?

News Thumbnail
12:51 PM | Thursday | Aug 6, 2026 Zacks Investment Research

ABBV Stock Dips 4% Despite Robust Q2: Buy the Dip or Stay Cautious?

News Thumbnail

AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool

3:26 PM | Friday | Aug 14, 2026

news photo
Loading...

AbbVie demonstrates resilient revenue growth fueled by its next-generation immunology and aesthetics portfolio. Bristol-Myers Squibb maintains high net margins while trading at a significant valuation discount to its peer.

Read full article redirect
3:26 PM | Friday | Aug 14, 2026

AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool

AbbVie demonstrates resilient revenue growth fueled by its next-generation immunology and aesthetics portfolio. Bristol-Myers Squibb maintains high net margins while trading at a significant valuation discount to its peer.

Read full article arrow
News Thumbnail
2:30 PM | Friday | Aug 14, 2026

Can ABBV's Neuroscience Drugs Drive Growth in the Second Half of 2026?

Zacks Investment Research

AbbVie's neuroscience franchise posts strong first-half growth, with Vyalev accelerating and tavapadon poised to add another potential growth driver.

Read full article arrow
News Thumbnail
7:15 AM | Friday | Aug 14, 2026

Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?

Fool - Investing News

Fidelity's lower 0.08% fee and broader 338-stock portfolio contrast sharply with iShares' concentrated pharma play, which delivered 60% returns in one year.

Read full article arrow
News Thumbnail
7:15 AM | Friday | Aug 14, 2026

Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?

Fool - Investing News

Fidelity's lower 0.08% fee and broader 338-stock portfolio contrast sharply with iShares' concentrated pharma play, which delivered 60% returns in one year.

Read full article arrow
News Thumbnail
7:53 AM | Thursday | Aug 13, 2026

Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More

247 Wallst

Wall Street analysts made bold moves Thursday, slashing targets on some names while dramatically upgrading others, and the gap between winners and losers tells a story about where smart money is quietly repositioning ahead of the next market move.

Read full article arrow
News Thumbnail
12:12 PM | Wednesday | Aug 12, 2026

The Energy and Pharma Giants Quietly Funding HDV's 3% Yield, and How Safe Each One Is

24/7 Wall Street

The iShares Core High Dividend ETF (NYSEARCA:HDV) leans hard on two sectors to fund its payout.

Read full article arrow
News Thumbnail
6:45 AM | Tuesday | Aug 11, 2026

AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?

The Motley Fool

AbbVie has been willing to supplement its new drug pipeline through acquisitions. It plans to pay $10.6 billion to purchase clinical-stage biotech company Apogee Therapeutics.

Read full article arrow
News Thumbnail
4:02 AM | Tuesday | Aug 11, 2026

AbbVie Inc. $ABBV Shares Sold by Contravisory Investment Management Inc.

Defense World

Contravisory Investment Management Inc. reduced its stake in shares of AbbVie Inc. (NYSE: ABBV) by 74.0% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 777 shares of the company's stock after selling 2,217 shares during the period.

Read full article arrow
News Thumbnail
9:45 AM | Monday | Aug 10, 2026

We Said These 4 Dividend Aristocrats Could Soar. Here's How They Did, Plus 3 New Picks.

24/7 Wall Street

About a year ago, 24/7 Wall St. flagged four overlooked Dividend Aristocrats as stealth growth plays, arguing that boring income names carried real upside if the market ever noticed.

Read full article arrow
News Thumbnail
9:44 AM | Monday | Aug 10, 2026

Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?

The Motley Fool

AbbVie's growth rate was more than 10% this past quarter and has been rising in recent years. Its valuation may seem high, but acquisition-related expenses have weighed on its bottom line.

Read full article arrow
News Thumbnail
8:00 AM | Monday | Aug 10, 2026

3 Beaten-Down Healthcare Stocks to Buy in August

24/7 Wall Street

Year to date, the healthcare sector finds itself in the middle of the S&P 500's pack.

Read full article arrow
News Thumbnail
4:24 PM | Friday | Aug 7, 2026

AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool

AbbVie relies on a high-margin biopharmaceutical portfolio and significant free cash flow to drive shareholder value. Abbott Laboratories leverages a highly diversified business model spanning medical devices, diagnostics, and nutritional products.

Read full article arrow
News Thumbnail
12:51 PM | Thursday | Aug 6, 2026

ABBV Stock Dips 4% Despite Robust Q2: Buy the Dip or Stay Cautious?

Zacks Investment Research

ABBV falls after cutting its 2026 EPS outlook to reflect the Apogee deal, despite strong Q2 results, higher revenue guidance and growth from key medicines.

Read full article arrow
News Thumbnail